PCRX News & Events

Pacira BioSciences presented real-world evidence from its Innovations in Genicular Outcomes Registry, IGOR, a first-of-its-kind multicenter, prospective, longitudinal observational registry. The first study demonstrated that Exparel was associated with improvements in pain, opioid use, function, and length of stay after receiving EXPAREL following total knee arthroplasty as compared to patients who received conventional bupivacaine and ropivacaine. The second study demonstrated that cryoneurolysis treatment with iovera was associated with longer-term improvement in pain and function for up to 12 months, relative to a typical improvement of outcomes for 4-6 months following alternative intra-articular agents. The data were presented at the American Academy of Orthopedic Surgeons, AAOS, 2026 Annual Meeting taking place March 2-6 in New Orleans, Louisiana.

Reports Q4 revenue $196.87M, consensus $201.93M. "2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients, generated $726 million in revenue, and achieved the highest gross margins in our company's history. Together, these results clearly validate the impact and promise of our 5x30 strategy," said Frank D. Lee, chief executive officer of Pacira BioSciences.

Sees FY26 gross margin 77%-79%. "Our performance continues to be led by EXPAREL, which is benefitting from expanding reimbursement, growing commercial adoption, and strengthened intellectual property providing protection into the 2040s. We further extended our commercial reach through strategic collaborations, while advancing clinical programs positioned to deliver a data-rich year. Pacira enters 2026 stronger than ever as we continue to redefine what is possible in innovative non-opioid pain management," continued Lee.